Witnessing the stock’s movement on the chart, on Wednesday, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) set off with pace as it heaved 1.88% to $14.62, before settling in for the price of $14.35 at the close. Taking a more long-term approach, ACAD posted a 52-week range of $13.40-$20.68.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 23.80%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -60.07%. This publicly-traded company’s shares outstanding now amounts to $166.71 million, simultaneously with a float of $165.49 million. The organization now has a market capitalization sitting at $2.39 billion. At the time of writing, stock’s 50-day Moving Average stood at $17.12, while the 200-day Moving Average is $16.83.
Acadia Pharmaceuticals Inc (ACAD) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Acadia Pharmaceuticals Inc’s current insider ownership accounts for 0.78%, in contrast to 99.22% institutional ownership. According to the most recent insider trade that took place on Apr 08 ’25, this organization’s EVP, CHIEF FINANCIAL OFFICER sold 2,708 shares at the rate of 14.82, making the entire transaction reach 40,133 in total value, affecting insider ownership by 59,456. Preceding that transaction, on Apr 08 ’25, Company’s PRINCIPAL ACCOUNTING OFFICER sold 1,028 for 14.82, making the whole transaction’s value amount to 15,235. This particular insider is now the holder of 22,257 in total.
Acadia Pharmaceuticals Inc (ACAD) Earnings and Revenue Records
Acadia Pharmaceuticals Inc’s EPS decrease for this current 12-month fiscal period is -60.07% and is forecasted to reach 0.95 in the upcoming year.
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Trading Performance Indicators
Let’s observe the current performance indicators for Acadia Pharmaceuticals Inc (ACAD). It’s Quick Ratio in the last reported quarter now stands at 2.32. The Stock has managed to achieve an average true range (ATR) of 0.73. Alongside those numbers, its PE Ratio stands at $10.75, and its Beta score is 0.51. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.50. Similarly, its price to free cash flow for trailing twelve months is now 15.23.
In the same vein, ACAD’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 1.36, a figure that is expected to reach -0.01 in the next quarter, and analysts are predicting that it will be 0.95 at the market close of one year from today.
Technical Analysis of Acadia Pharmaceuticals Inc (ACAD)
Going through the that latest performance of [Acadia Pharmaceuticals Inc, ACAD]. Its last 5-days volume of 1.42 million was inferior to the volume of 2.25 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 57.63% While, its Average True Range was 0.73.
Raw Stochastic average of Acadia Pharmaceuticals Inc (ACAD) in the period of the previous 100 days is set at 16.76%, which indicates a major fall in contrast to 40.26% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 53.62% that was higher than 45.68% volatility it exhibited in the past 100-days period.
